SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is seeing intense conversation and volatility after reports of increased CME margin requirements led to a significant pullback, with some speculating about forced liquidations from a major bank. The community is sharply divided, as bulls view this dip as a prime buying opportunity, citing supply shortages and strong industrial demand, while bears caution that it's a classic pump-and-dump leaving retail investors exposed.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending on the back of positive preliminary results from its Phase III FLAMINGO-01 study, which showed an impressive ~80% reduction in breast cancer recurrence rates from its open-label arm. This news, coupled with an extended insider share lock-up, is fueling strong community confidence as investors actively discuss the potential for a significant short squeeze due to the stock's low float, high short interest, and soaring Cost To Borrow rates.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is experiencing significant discussion following a sharp pullback in precious metals, which the community largely attributes to increased CME margin requirements for futures and a major silver futures liquidation event. Traders are actively debating whether this represents a healthy liquidity flush and a buying opportunity, or if it signals the peak of the recent rally amid concerns over market manipulation and 

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is generating significant buzz as its Anaphylm oral epinephrine film approaches a pivotal FDA PDUFA date on January 31, 2026, with the agency waiving an advisory committee review. Community sentiment is sharply divided between highly confident bulls anticipating approval, a substantial short squeeze, and a disruptive market entry due to the film's convenience, versus skeptics who cite the company's past regulatory setbacks and rising short interest as potential headwinds. The debate centers on Anaphylm's potential to redefine emergency anaphylaxis treatment against existing auto-injectors and nasal sprays, amidst broader discussions about epinephrine accessibility.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending amidst a divided community, where recent analyst upgrades and anticipation for potential CES 2026 announcements are juxtaposed against significant stock underperformance. While many bulls emphasize its robust backlog and zero debt as strong fundamentals, skeptics highlight ongoing insider selling and unfulfilled partnership promises. This has left investors frustrated with the stock's current volatility and its inability to participate in broader market rallies.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending following its recent inclusion in the Russell 2000 and 3000 indexes, a catalyst typically associated with increased institutional visibility. However, community sentiment is heavily polarized, with many questioning the stock's persistent decline despite this positive development and the company's profitability, attributing the weakness to ongoing selling pressure and SPAC-related overhang. Discussion ranges from bearish predictions of new lows and accusations of market manipulation to long-term investors highlighting user growth and anticipating a future recovery.

ProShares Trust - ProShares UltraShort Silver -2x Shares

ProShares UltraShort Silver

ProShares UltraShort Silver ($ZSL) is trending as silver experiences a significant pullback, fueled by increased margin requirements from the CME. The community is actively discussing silver's recent parabolic rally and overbought conditions, with many viewing $ZSL as an opportunity to capitalize on an anticipated correction in the precious metal.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is trending amid a dramatic surge in silver prices, largely attributed to escalating physical demand from China and anticipation of a potential Chinese export ban by early 2026. The community is highly engaged, with many predicting silver will reach unprecedented levels like $200-$1000 per ounce, fueled by a perceived short squeeze and vital industrial demand from AI and EV sectors. While AGQ's 2x leverage amplifies these movements, some traders caution about potential profit-taking and an overbought market after such a rapid ascent.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical (RARE) is trending due to the announcement that its Phase 3 trials for setrusumab in Osteogenesis Imperfecta failed to meet primary endpoints, causing a significant stock plunge. This was further impacted by a Complete Response Letter from the FDA for its UX111 gene therapy, citing manufacturing issues that are now being addressed. The community is sharply divided, debating if the steep sell-off is an overreaction and a potential buying opportunity, or if these setbacks signal deeper concerns for the rare disease focused company.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo Inc. (MLGO) is a highly contentious stock, with recent news of a quantum entanglement-based training algorithm and S&P Global BMI Index inclusion sparking conversation. However, the community remains sharply divided, with many labeling it a "China Hustle" scam due to historical dilution and reverse splits. Others are bullish, citing its quantum AI focus, profitability, and cash-rich status as indicators of significant undervaluation and potential for a massive squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ECDA look like .71-.75 is the Buy zone…. hmmmm

Sandy

StockTwits Web

ECD Auto Design

 look like .71-.75 is the Buy zone…. hmmmm